	US 12,329,812 B2
	Nucleic acid vaccines
Giuseppe Ciaramella, Sudbury, MA (US); Axel Bouchon, Kleinmacknow (DE); and Eric Yi-Chun Huang, Boston, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, INC., Cambridge, MA (US)
Filed on Aug. 12, 2024, as Appl. No. 18/801,174.
Application 18/801,174 is a continuation of application No. 17/683,171, filed on Feb. 28, 2022.
Application 17/683,171 is a continuation of application No. 16/144,394, filed on Sep. 27, 2018.
Application 16/144,394 is a continuation of application No. 16/036,318, filed on Jul. 16, 2018.
Application 16/036,318 is a continuation of application No. 15/089,050, filed on Apr. 1, 2016, granted, now 10,022,435, issued on Jul. 7, 2018.
Application 15/089,050 is a continuation of application No. PCT/US2015/027400, filed on Apr. 23, 2015.
Claims priority of provisional application 62/088,994, filed on Dec. 8, 2014.
Claims priority of provisional application 61/983,250, filed on Apr. 23, 2014.
Prior Publication US 2024/0398931 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 7/00 (2006.01); A61K 9/00 (2006.01); A61K 9/1271 (2025.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61K 39/155 (2006.01); A61K 39/39 (2006.01); A61K 48/00 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/145 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1271 (2013.01); A61K 9/5123 (2013.01); A61K 9/5146 (2013.01); A61K 31/7105 (2013.01); A61K 39/12 (2013.01); A61K 39/155 (2013.01); A61K 39/39 (2013.01); A61K 48/00 (2013.01); C12N 7/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16234 (2013.01)]

1 Claim

1. A vaccine comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle, wherein the mRNA comprises an open reading frame encoding an influenza hemagglutinin protein, wherein the open reading frame comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine, and wherein the vaccine comprises from 25-100 μg of the mRNA.